Far Infrared Radiation Treatment for Bipolar Condition

The recruitment status of this study is unknown because the information has not been verified recently.
Verified August 2009 by GAAD Medical Research Institute Inc..
Recruitment status was  Active, not recruiting
Sponsor:
Information provided by:
GAAD Medical Research Institute Inc.
ClinicalTrials.gov Identifier:
NCT00573196
First received: December 12, 2007
Last updated: August 14, 2009
Last verified: August 2009
  Purpose

A preliminary study to determine the possibility of using far infrared radiation for the treatment of the Bipolar Condition


Condition Intervention Phase
Bipolar Disorder
Radiation: Far infrared
Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Phase 1 Study to Evaluate the Efficacy of Using Energy Specific Far Infrared Radiation Treatment for Bipolar Condition

Resource links provided by NLM:


Further study details as provided by GAAD Medical Research Institute Inc.:

Primary Outcome Measures:
  • The primary end point is to determine the therapeutic effects of far infrared radiation on bipolar condition. [ Time Frame: 2 years ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • The secondary end point of the study is to evaluate the therapeutic effects of far infrared radiation on other related mental illness including Depression, Anxiety, Stress and Insomnia. [ Time Frame: 2 years ] [ Designated as safety issue: No ]

Enrollment: 3
Study Start Date: September 2006
Estimated Study Completion Date: June 2008
Primary Completion Date: February 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1 Radiation: Far infrared
Far infrared radiation (5μm to 15μm wavelength)

Detailed Description:

A 2000 study in the American Journal of Psychiatry reported that, "in those with bipolar, two major areas of the brain contain 30 percent more cells that send signals to other brain cells". This fact explains why famous people with the Bipolar condition like astronaut Buzz Aldrin, financier Robert Campeau, British Prime Minister Winston Churchill, composer Mozart, scientist Isaac Newton, physician Sigmund Freud and media giant & entrepreneur Ted Turner, excelled in life due to the additional brain power!

The excessive brain power, however, had to be controlled occasionally with mood stabilizers. Mood stabilizers include a number of anticonvulsants and Lithium. These medications, however, have adverse side effects on the kidneys. The proposed evaluation does not have any adverse health effects.

  Eligibility

Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Persons with Bipolar Condition, Depression, Anxiety, Stress and Insomnia

Exclusion Criteria:

  • Persons with severe mental illness that are confined to mental hospitals etc. as defined by the USA Diagnostic and Statistical Manual of Mental Disorders (DSM) are excluded from this clinical trial.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00573196

Locations
Canada, Ontario
The Centre for Incurable Diseases
Mississauga, Ontario, Canada, L5R 3G9
Sponsors and Collaborators
GAAD Medical Research Institute Inc.
Investigators
Principal Investigator: Kwasi Donyina, Ph.D. GAAD Medical Research Institute Inc.
Study Director: Ken Nedd, M.D. GAAD Medical Research Institute Inc.
  More Information

No publications provided

Responsible Party: Dr. Kwasi Donyina/Founder & President, GAAD Medical research Institute Inc.
ClinicalTrials.gov Identifier: NCT00573196     History of Changes
Other Study ID Numbers: GAAD-BPC-CTP1
Study First Received: December 12, 2007
Last Updated: August 14, 2009
Health Authority: Canada: Health Canada

Keywords provided by GAAD Medical Research Institute Inc.:
Affective Psychosis, Bipolar
Depression, Bipolar
Mania
Manic Disorder
Manic State
Manic-Depressive Psychosis
Psychoses, Manic-Depressive
Psychosis, Manic-Depressive

Additional relevant MeSH terms:
Bipolar Disorder
Affective Disorders, Psychotic
Mental Disorders
Mood Disorders

ClinicalTrials.gov processed this record on October 21, 2014